Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6076 to 6090 of 8314 results

  1. Monitoring inhaler technique:- What is the current frequency and the current method being used to check the inhaler technique of people with asthma? What is the optimal frequency and the best method of checking inhaler technique to improve clinical outcomes for people with asthma?

    Recommendation ID NG80/4 Question Monitoring inhaler technique:- What is the current frequency and the current method being used to check

    Research recommendation
    Published
    18 October 2018

  2. Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine assessment and monitoring of changes in pulmonary status in people with cystic fibrosis?

    Recommendation ID NG78/3 Question Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine

    Research recommendation
    Published
    6 November 2018

  3. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Recommendation ID CG173/1 Question What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy

    Research recommendation
    Published
    26 October 2020

  4. Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Recommendation ID CG173/1 Question Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness

    Research recommendation
    Published
    9 June 2015

  5. There is uncertainty about how much remote monitoring devices would affect resource use in the NHS and personal social services. Some impacts may not have been included in the external assessment group's (EAG) model because of a lack of data (see section 3.12 ), including resource use related to carers (see section 3.13 ). Adopting the technologies may change how care is provided (see section 3.4 ) so their effect on resources is hard to estimate without direct data. So, the committee recommended collecting data on how much using the devices affects resource use, to inform cost-effectiveness estimates. Data on time dedicated to training and spent reviewing device results should also be collected. The broader impact on services provided by Parkinson's specialist teams and carers should be considered.

    Recommendation ID DG51/01 Question There is uncertainty about how much remote monitoring devices would affect resource use in the NHS and

    Research recommendation
    Published
    7 March 2023

  6. How much using remote monitoring devices to guide decisions about care affects symptoms, and therefore health-related quality of life, is uncertain. How long after using the devices any impact would last is also uncertain. This had a sizeable influence on cost-effectiveness estimates (see section 3.10 ). Data on this came from studies that did not represent likely NHS practice (see section 3.6 ), which is itself uncertain (see section 3.3 ), and from assumptions made by the EAG because of lack of data. For its model, the EAG used a published algorithm from Chandler et al. (2020) to estimate quality-adjusted life years (QALYs) from the Unified Parkinson's Disease Rating Scale (UPDRS) domain scores. The clinical experts said that health-related quality of life questionnaires like the PDQ‑39 are increasingly used in trials to assess health-related quality of life for people with Parkinson's disease. The committee also recognised that the effect of the devices on the health-related quality of life of carers had not been included in the EAG's model because of a lack of data (see section 3.13 ).

    Recommendation ID DG51/02 Question How much using remote monitoring devices to guide decisions about care affects symptoms, and therefore

    Research recommendation
    Published
    7 March 2023

  7. More research is needed on the following artificial intelligence (AI)‑derived software to analyse chest X‑rays alongside clinician review for suspected lung cancer in adults referred from primary care:

    Recommendation ID HTE12/1 Question More research is needed on the following artificial intelligence (AI)‑derived software to analyse chest

    Research recommendation
    Published
    11 January 2024

  8. More research is needed on the following key outcomes:

    Recommendation ID HTE12/1 Question More research is needed on the following key outcomes: Any explanatory notes(if applicable)

    Research recommendation
    Published
    11 January 2024

  9. More research is needed on using the following digital weight-management technologies:

    Recommendation ID HTE14 Question More research is needed on using the following digital weight-management technologies: Any explanatory

    Research recommendation
    Published
    11 January 2024

  10. More research is recommended on UroShield for preventing catheter associated urinary tract infections (UTIs). It has potential to provide significant patient and healthcare system benefits but uncertainties in the evidence need to be addressed. Research should be comparative, and it should address uncertainties about the effectiveness of UroShield in preventing catheter-associated UTIs and other catheter-related complaints such as blockages. Find out more in the further research section of this guidance.

    Recommendation ID MTG69/01 Question More research is recommended on UroShield for preventing catheter associated urinary tract infections

    Research recommendation
    Published
    8 April 2022

  11. More research or data collection is recommended on Sleepio for people who are eligible for face-to-face cognitive behavioural therapy for insomnia (CBT-I) in primary care. This is because there is limited clinical evidence to show how effective Sleepio is compared with face-to-face CBT-I. A real-world study is suggested to compare the effectiveness of Sleepio with face-to-face CBT-I.

    Recommendation ID MTG70/01 Question More research or data collection is recommended on Sleepio for people who are eligible for face-to-face

    Research recommendation
    Published
    31 May 2022

  12. More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee replacement would decrease the uncertainty of the clinical and cost effectiveness of these treatments. Trials directly comparing apixaban with rivaroxaban, dabigatran etexilate and fondaparinux would strengthen the evidence base for these comparisons.

    Recommendation ID TA245/1 Question More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee

    Research recommendation
    Published
    9 June 2015

  13. NICE recommends research generating and analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim.

    Recommendation ID TA293/2 Question NICE recommends research generating and analysing observational data including, but not limited to,

    Research recommendation
    Published
    9 June 2015

  14. [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.

    Recommendation ID TA161/2 Question [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the

    Research recommendation
    Published
    9 June 2015

  15. NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system in detecting sentinel lymph node metastases during breast cancer surgery. It also recommends that data on all patients having whole lymph node analysis by the RD-100i OSNA system should be submitted to this registry. These data should be integrated with data from other registries for breast cancer where appropriate.

    Recommendation ID DG8/1 Question NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system

    Research recommendation
    Published
    9 June 2015